Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative tislelizumab plus SOX/XELOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400083389Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tislelizumab and oxaliplatin, sponsored by Zhejiang Cancer Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tislelizumaboxaliplatin
Beyond the preview
Go deeper on ChiCTR2400083389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083389.